[Economic assessment of Caelyx versus topotecan in advanced ovarian cancer].

MLA

Girre, Véronique, et al. “[Economic Assessment of Caelyx versus Topotecan in Advanced Ovarian Cancer].” Bulletin Du Cancer, vol. 90, no. 11, Nov. 2003, pp. 983–88. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=14706902&authtype=sso&custid=ns315887.

APA

Girre, V., Pujade-Lauraine, E., & Durand-Zaleski, I. (2003). [Economic assessment of Caelyx versus topotecan in advanced ovarian cancer]. Bulletin Du Cancer, 90(11), 983–988.

Chicago

Girre, Véronique, Eric Pujade-Lauraine, and Isabelle Durand-Zaleski. 2003. “[Economic Assessment of Caelyx versus Topotecan in Advanced Ovarian Cancer].” Bulletin Du Cancer 90 (11): 983–88. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=cmedm&AN=14706902&authtype=sso&custid=ns315887.